Why the study?
To evaluate the effectiveness and associated risks of rivaroxaban compared to warfarin in Chinese elderly diabetic patients with non-valvular atrial fibrillation.
Does rivaroxaban reduce thromboembolic events and bleeding compared to warfarin in Chinese elderly diabetic patients with non-valvular atrial fibrillation?
Does rivaroxaban reduce thromboembolic events and bleeding compared to warfarin in Chinese elderly diabetic patients with non-valvular atrial fibrillation?
In elderly Chinese diabetic patients with non-valvular atrial fibrillation, rivaroxaban was associated with significantly lower risks of ischemic stroke, major bleeding, and mortality compared to warfarin over 3 years.
Answers are grounded in this paper and cite their sources.
Rivaroxaban was associated with lower thromboembolic risk than warfarin; leaves open confirmation via randomized trials in this population.
Purpose: To evaluate the effectiveness and associated risks of rivaroxaban against warfarin in Chinese elderly diabetic patients with non-valvular atrial fibrillation.Methods: Data regarding demographical characteristics, clinical conditions, ischemic stroke, intracranial bleeding, gastrointestinal tract bleeding, myocardial infractions, hip/pelvic fracture, asthma, breast/prostate cancer, and death during 3-years of treatment of 584 Chinese diabetic patients with confirmed non-valvular atrial fibrillation who were placed on rivaroxaban (RX Cohort, n = 201) or warfarin (WF Cohort, n = 383) were collected from hospital records and analyzed. Multivariate analysis was performed for the prediction of the incidence of the treatment-emergent event(s).Results: During the 3-year treatment period, higher numbers of patients were reported for intracranial bleeding (p = 0.042), ischemic stroke (p = 0.042), gastrointestinal bleeding (p = 0.0006), hip/pelvic fracture (p = 0.042), and asthma (p = 0.0007) in WF cohort than RX cohort. Also, higher mortality was reported in WF cohort than for RX cohort (24 vs. 4, p = 0.024). Female sex (p = 0.031), age (p = 0.035), and comorbidities (p = 0.021) were associated with incidence of treatment-emergent event(s).Conclusion: With rivaroxaban, a significant and safe risk-reduction of thromboembolic events are found in elderly diabetic patients with non-valvular atrial fibrillation. Keywords: Anticoagulant, Diabetes, Non-valvular atrial fibrillation, Rivaroxaban, Warfarin
No takes yet. Share an insight, caveat, or question.
Wang et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: